4D-150

AXP000259.1 · Viral vector gene therapy

Platform
AAV R100 capsid (4DMT)
Originator
4D Molecular Therapeutics
Sponsor
4D Molecular Therapeutics

Names

NameTypeSource
4D-150preferred name, codecurator, ctgov

Virus

Role
In vivo gene transfer
Family
Parvoviridae
Virus
adeno-associated virus (R100 capsid variant)
Strain
R100
Replication
non replicating
Modifications
synthetic capsid-derived sequence (R100), for intravitreal delivery
Route
intravitreal
Source
evidence

Approvals

No regulatory approval recorded.

Clinical trials (5)

TrialTitleStatusPhaseStartPrimary completionEnrolmentConditions
NCT07867080A Phase 3 Trial for Intravitreal Injection of 4D-150 in Adults With Diabetic Macular Edema (DME).RecruitingPhase 32026-09-182029-01514Diabetic Macular Edema (DME)
NCT07064759Single Intravitreal (IVT) Injection of 4D-150 in Patients With Macular Neovascularization Secondary to Age-Related Macular DegenerationRecruitingPhase 32025-07-222027-11480Neovascular Age-Related Macular Degeneration (nAMD)
NCT068649884D-150 in Patients With Macular Neovascularization Secondary to Age-Related Macular DegenerationActive not recruitingPhase 32025-03-032027-06480Macular Neovascularization Secondary to Age-Related Macular Degeneration
NCT059305614D-150 in Patients With Diabetic Macular EdemaActive not recruitingPhase 22023-08-092029-02-2872Diabetic Macular Edema; Diabetic Retinopathy
NCT051972704D-150 in Patients With Neovascular (Wet) Age-Related Macular DegenerationRecruitingPhase 1/22021-12-092027-03215Neovascular (Wet) Age-Related Macular Degeneration

Recent changes

No changes recorded in its trials yet.

Clinical papers

PubMedTitleJournalYearLinked by
PMID 39620832Design and Characterization of a Novel Intravitreal Dual-Transgene Genetic Medicine for Neovascular Retinopathies.Investigative ophthalmology & visual science2024cited by trial NCT05197270

Other papers

Preclinical studies, reviews and other papers that name it.

PubMedTitleJournalYearLinked by
PMID 41490387Emerging solutions for neovascular age-related macular degeneration.Current opinion in ophthalmology2026name in abstract: 4D-150
PMID 41688763AAV-based gene therapies for neovascular AMD.Gene therapy2026name in abstract: 4D-150
PMID 39379521Exploring new horizons in neovascular age-related macular degeneration: novel mechanisms of action and future therapeutic avenues.Eye (London, England)2025name in abstract: 4D-150
PMID 40293479Gene therapy in neovascular age related macular degeneration: an update.Graefe's archive for clinical and experimental ophthalmology = Albrecht von Graefes Archiv fur klinische und experimentelle Ophthalmologie2025name in abstract: 4D-150
PMID 40319468Beyond the injection: delivery systems reshaping retinal disease management.Expert opinion on pharmacotherapy2025name in abstract: 4D-150
PMID 40364236Gene Therapy in Diabetic Retinopathy and Diabetic Macular Edema: An Update.Journal of clinical medicine2025name in abstract: 4D-150
PMID 38927656Gene Therapy for Non-Hereditary Retinal Disease: Age-Related Macular Degeneration, Diabetic Retinopathy, and Beyond.Genes2024name in abstract: 4D-150

Notes

Intravitreal gene therapy for neovascular AMD on 4DMT's customised R100 capsid, designed to block more than one VEGF family member. Phase 1/2 NCT05197270 (published) and phase 3 NCT07064759 (4FRONT programme). The exact transgene cargo is not taken from a primary source here, so `transgenes` is empty.

How to cite

4D-150 (AXP000259.1). The Abstractinator program registry, release 2026-11-17+2c46e992acfc. https://abstractinator.me/registry/AXP000259.html

Something wrong or missing? Suggest a correction (a GitHub issue; please link your evidence). Entry created 2026-11-11, updated 2026-11-11.